Abstract 968P
Background
Current guidelines for hepatocellular carcinoma (HCC) screening in patients with chronic liver disease (CLD) recommend ultrasound with or without alpha-fetoprotein (AFP) every 6 months. The sensitivity of AFP and USG are low for early stage HCC. Following our previous study which identified a novel routine blood test signature for HCC, this study aims to develop a high-dimensional data classifier which accounts for the intricate interactions between these blood parameters for the detection of HCC. Its performance is then compared with AFP.
Methods
Records from 2000 to 2018 were retrieved from a population-based clinical database of >200k patients, the Hong Kong Hospital Authority Data Collaboration Laboratory. CLD (hepatitis/ cirrhosis) patients with and without HCC were identified with ICD codes, antiviral drug history, virology test and radiology reports. Decompensated cases were excluded. Blood records within one month before the diagnosis of HCC and CLD patients were retrieved. The records retrieved included all components of CBC, LFT, RFT and clotting profile. Data from 2000-2015 were split into training and testing cohorts in an 8:2 ratio while data from 2016-2018 were used as the validation set. Machine learning models were applied and their performances were compared with AFP.
Results
The cohort yielded 223,862 patients including 31,149 with HCC (45.9% hepatitis-associated) and 192,713 without. Results from the test set (n = 12528; 3279 HCC) showed promise in safely excluding non-HCC patients with a sensitivity of 90% and negative predictive value of 97%. The model’s high sensitivity maintained steady from late to early stage HCC while that of AFP halved. Our model increases HCC detection rate via USG from 19% to 50% compared to current protocol, indicating potential use in imaging prioritization and cost-saving in HCC surveillance.
Conclusions
An AI classifier for HCC detection is developed from routine blood test patient data. Its performance tested using an ultra-large cohort is consistently high without degradation across all stages with marked superiority to AFP for early stage HCC detection. Currently, multicenter prospective validation is being performed in Hong Kong.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong University of Science and Technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18